Archive for the News Category

Ceapro Reports 2017 Third Quarter Business Update and Financial Results – Recent entry into the cosmeceuticals sector with launch of proprietary line of products – Company continues advancement for expansion into the nutraceutical market – Completion of bio-efficacy study evaluating avenanthramides in exercise-induced inflammation with results expected by year-end – Results from animal studies evaluating bioavailability of impregnated CoQ10 with beta glucan expected Q1 2018

EDMONTON, ALBERTA – November 15, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”) a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and nine-month periods ended September 30,

Read more

Ceapro Inc. Announces the Launch of its Proprietary Line of Cosmeceutical Products, JUVENTE – Successful execution of JuventeDC Inc. acquisition marks an important step in Ceapro’s strategic market diversification business plan – New anti-aging skin care product line represents $5B market opportunity and utilizes Ceapro’s active ingredients beta glucan and avenanthramides

EDMONTON, ALBERTA – October 26, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its entry into the end-user cosmeceuticals market through the acquisition of Quebec-based

Read more

Ceapro Reports 2017 Second Quarter Business Update and Financial Results – Continued advancement for expansion into nutraceutical market – Results from animal studies evaluating bioavailability of impregnated CoQ10 with beta glucan expected Q4 2017 – Encouraging preliminary data from bio-efficacy study evaluating avenanthramides in exercise-induced inflammation warrant extension to evaluate additional biomarkers

EDMONTON, ALBERTA – August 18, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”) a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30,

Read more

Ceapro Announces Results of 2017 Shareholders’ Meeting

EDMONTON, ALBERTA – June 5, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William

Read more

Ceapro Inc. Announces its First Major Milestones with its PGX Enabling Technology – Company announces completion of PGX pilot scale facility, installation of custom-designed process equipment, and formation of expert PGX team – Agreement with University of Alberta, utilizing $332K grant from Canadian Government, signed to conduct impregnation studies using PGX technology – Bioavailability study for new chemical entity CoQ10-beta glucan to commence this month

EDMONTON, ALBERTA – June 1, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided an update of the Company’s Pressurized Gas eXpanded (“PGX”) technology and announced

Read more

Ceapro Inc. to Provide a Corporate Update to Shareholders on June 1, 2017

EDMONTON, ALBERTA – May 26, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will provide

Read more

Ceapro Inc. Reports 2017 First Quarter Development Highlights and Financial Results – Company well positioned for expansion into nutraceutical market – Company to advance beta glucan functional drink formulation into its next stage of development – Topline data from bio-efficacy study evaluating avenanthramides in exercise-induced inflammation expected in the near-term

EDMONTON, ALBERTA – May 17, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the three months ended March 31, 2017 and

Read more

Ceapro Inc. Demonstrates First Water Soluble Solid Nanodispersion Formulation of CoQ10 Utilizing its PGX Enabling Technology – Announces positive results from the first phase of a project to develop a functional energy drink at the 16th European Meeting on Supercritical Fluid Technologies held in Lisbon, Portugal

EDMONTON, ALBERTA – May 4, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful completion of the first development phase of a project entitled,

Read more

Ceapro Inc. Reports 2016 Financial Results and Provides Corporate Update – Company reports highest full year revenues in Company’s history and continues to deliver strong performance

EDMONTON, ALBERTA – April 6, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve months ended December 31, 2016 and

Read more

Ceapro Inc. Announces Conversion of Convertible Debentures to Equity and the Grant of Stock Options

EDMONTON, ALBERTA – January 4, 2017 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that holders of $960,000 of convertible debentures due December 31, 2016 have

Read more
Page 1 of 1112345...10...Last »